In the process of establishing a troponin I assay in our laboratory, we found limited data on reference intervals for plasma. Because our laboratory relies heavily on plasma rather than serum to expedite analysis (1 ), we undertook a parallel study of serum and plasma troponin I concentrations with the Abbott AxSYM TM assay. To our surprise, we found several discordant results ( Table 1) . Reanalysis of the samples reproduced the discrepant results. However, when one of the serum samples was recentrifuged, reanalysis produced results essentially the same as those obtained from the matching plasma sample. After the other discordant serum samples were recentrifuged and reanalyzed, all serum and plasma results were similar. Additional samples, purposely allowed to contain tiny fibrinstrands, also produced increased troponin I results.
To the Editor:
In the process of establishing a troponin I assay in our laboratory, we found limited data on reference intervals for plasma. Because our laboratory relies heavily on plasma rather than serum to expedite analysis (1 ), we undertook a parallel study of serum and plasma troponin I concentrations with the Abbott AxSYM TM assay. To our surprise, we found several discordant results ( Table 1) . Reanalysis of the samples reproduced the discrepant results. However, when one of the serum samples was recentrifuged, reanalysis produced results essentially the same as those obtained from the matching plasma sample. After the other discordant serum samples were recentrifuged and reanalyzed, all serum and plasma results were similar. Additional samples, purposely allowed to contain tiny fibrinstrands, also produced increased troponin I results.
We believe that the antibody either binds nonspecifically to fibrin or that the indicator enzyme is physically trapped by fibrin in the separation matrix. Because incomplete separation of serum can leave fibrin in the sample, falsely increased troponin I concentrations can result.
We concluded that the use of plasma rather than serum essentially eliminates this problem and also allows the samples to be placed on the AxSYM faster, expediting turnaround time by at least 10 -15 min. However, if serum is used, the samples must be completely clotted and centrifuged sufficiently to ensure complete separation of the serum from the clot. In our laboratory, we have found that centrifugation at 2000g for 10 min is required for the preparation of fibrin-free serum. To the Editor: This letter highlights the important issue of sample preparation and that poor sample integrity can adversely affect assay methodologies, regardless of the highly specific nature of the reagents. For assays using serum, it is important to ensure that complete clot formation has taken place before centrifugation. It should also be noted that some specimens, especially those from patients receiving anticoagulant or thrombolytic therapy, may exhibit increased clotting time. If specimens are centrifuged before complete clot formation, the presence of fibrin may alter results. 
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More on the Analog Free-Testosterone Assay
To the Editor:
In their recent article, Winters et al. (1 ) reported free and bioavailable testosterone in 28 purportedly healthy men with widely ranging body mass indexes. The authors showed that total and free, but not bioavailable, testosterone correlated positively with sex hormone-binding globulin (SHBG) and concluded that SHBG concentrations influenced free-testosterone concentrations as measured by the analog assay.
We have also measured free testosterone, total testosterone, and SHBG, using the same kits from Diagnostic Products Corp. in 40 healthy volunteers (Fig. 1) . Like Winters et al.
(1 ), we found a correlation (r ϭ 0.54) between total testosterone and SHBG, with total testosterone (nmol/L) ϭ 0.17 SHBG (nmol/L) ϩ 11.3. However, we found no statistically significant correlation (r ϭ 0.05) between free testosterone and SHBG, with free testosterone (pmol/L) ϭ Ϫ0.05 SHBG (nmol/L) ϩ 63.3. We noted an apparent error in the y-axis scale for free testosterone in their Figs. 1 and 3 ; the values ranged between 0 and 3 pmol/L, not in keeping with the range of free testosterone in their subjects as stated in Table 1 .
Their additional studies do not appear to support SHBG affecting the analog assay. First, their finding of lower than expected free-testosterone concentrations in male serum diluted with pregnant serum, which contains high SHBG concentrations, contradicted their hypothesis. This is not unexpected because the addition of binding protein in a closed in vitro system leads to re-equilibration of the free hormone to binding sites, as determined by the equilibrium con- 
